References

 

 

  1. Anderson R et al. Accuracy in equianalgesic dosing: conversion dilemmas. J Pain Sym Manage. 2001; 21:397-406
  2. Bruera E, Pereira J, Watanabe S et al. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 1996;78(4):852-57
  3. Dale O, Moksnes K, Kaasa S. European Palliative Care Research Collaborative pain guidelines: Opioid switching to improve analgesia or reduce side effects. A systematic review. Palliative Medicine 2011;25:494-503
  4. Faculty of Pain Medicine. Principles regarding the use of opioid analgesics in patients with chronic non-cancer pain. 2010
  5. Fine PG, Portenoy RK. Establishing \"Best Practices\" for Opioid Rotation: Conclusions of an Expert Panel. J Pain Sym Manage 2009;38:418-425
  6. Glare PA, Walsh TD. Dose-ranging study of oxycodone for chronic pain in advanced cancer. J Clin Oncol. 1993;11(5):973-8
  7. Hagen NA, Babul N. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain\". Cancer. 1997;79(7):1428-37
  8. Houde R, Wallenstein S, Beaver W. Evaluation of analgesics in patients with cancer pain. Clin Pharm. 1966;1:59–97
  9. Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther. 1990; 47(5): 639-46
  10. Kalso E, Vainio A et al. Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays. Pharmacol Toxicol. 1990; 67(4):322-28
  11. Knotkova H, Fine PG, Portenoy RK. Opioid Rotation: The science and the limitations of the equianalgesic dose table. J Pain Sym Manage 2009;38:426-439
  12. Mahler DL, Forrest WH. Relative analgesic potencies of morphine and hydromorphone in postoperative pain. Anesthesiology 1975;42(5):602–607
  13. Mercadante S, Caraceni A. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliative Medicine 2011;25(5):504-515
  14. Pereira J, Lawlor P, Vigano A et al. Equianalgesic dose ratios of opioids: a critical review and proposals for long-term dosing. J Pain Sym Manage 2001;22:672-687
  15. Sittl R, Likar R, Nautrup BP. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin Ther. 2005;27(2):225-37
  16. Skaer TL. Dosing considerations with transdermal formulations of fentanyl and buprenorphine for the treatment of cancer pain. J Pain Research 2014;7:495-503
  17. The Royal Australasian College of Physicians. Prescription Opioid Policy: Improving management of chronic non-malignant pain and prevention of problems associated with prescription opioid use. Sydney 2008
  18. Endo Pharmaceuticals approved Opana ER (Oxymorphone HCI) consumer medicine product information. December 2014.
  19. The New York City Department of Health and Mental Hygiene. Morphine milligram equivalent (mme) calculator [Internet]. n.d.; From: http://www.nyc.gov/html/doh/html/mental/MME.html. Accessed 16 September 2015.
  20. Pharmacist US. Opioid pharmacology and considerations in pain management [Internet]. 2007. From: http://www.uspharmacist.com/continuing_education/ceviewtest /lessonid/105473/. Accessed 16 September 2015.
  21. Endo Pharmaceuticals approved Opana ER (Oxymorphone HCI) consumer medicine product information. December 2014.
  22. Franklin GM. Opioids for chronic noncancer pain: A position paper of the american academy of neurology. Neurology. 2014;83(14):1277-1284.
  23. Franklin GM, Rahman EA, Turner JA, Daniell WE, Fulton-Kehoe D. Opioid use for chronic low back pain: A prospective, population-based study among injured workers in washington state, 2002-2005. Clin J Pain. 2009;25(9):743-751.